TMCnet News
RETA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Reata Pharmaceuticals, Inc. Is Fair to ShareholdersHalper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) to Biogen Inc. for $172.50 per share in cash is fair to Reata shareholders. Halper Sadeh encourages Reata shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Reata and its board of directors violated the federa securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Reata shareholders; (2) determine whether Biogen is underpaying for Reata; and (3) disclose all material information necessary for Reata shareholders to adequately assess and value the merger consideration. On behalf of Reata shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. Halper Sadeh encourages Reata shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230728605217/en/ |
